
    
      Open-label pilot (Phase II) study to assess the immunologic activity of a cellular vaccine
      composed of killed allogeneic tumor cells (1650-G) and GM-CSF in patients with stage I-IIIA
      NSCLC after definitive therapy. (Surgery, Surgery plus Radiation Therapy, or Surgery,
      Radiation Therapy plus Adjuvant Chemotherapy).
    
  